|

CREXONT ER Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: IPX203

Pipeline

Phase 4: 2

Top Sponsors

  • The Cleveland Clinic1
  • Impax Laboratories, LLC1

Indications

  • Parkinson's Disease2
  • Parkinson Disease2

Phoenix, Arizona1 trial

A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

Barrow Neurological Institute

Phase 4

Cleveland, Ohio1 trial

BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease

Cleveland Clinic

Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.